Glaxosmithkline S.a.e. · EGX:BIOC
Glaxosmithkline S.a.e — GlaxoSmithKline Pharmaceuticals — Q1 FY2026-27 Earnings Presentation
8 slides from Glaxosmithkline S.a.e's earnings presentation, Aug 3, 2026
Slide 1: GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited gsk.com
Slide 2: Bhushan Akshikar, Managing Director; Ronojit Biswas, Chief Financial Officer
Bhushan Akshikar, Managing Director Mr. Bhushan Akshikar has been the MD of GSK India since Q3 2022. He brings over 15 years of leadership experience within GSK in key roles across India, Middle East, Russia CIS & Africa region. Prior to joining GSK, Bhushan spent 15 years with Johnson & Johnson, in
Slide 3: GSK India's Key Focus areas to drive growth aligned to global priorities
GSK India’s Key Focus areas to drive growth aligned to global priorities Deliver Accelerate Simplify how growth R&D we work Established portfolio – deliver competitive Focus on innovation & accelerate launch Reduce complexity, focus resources on performance; of pipeline products what matters most an
Slide 4: IPM Q1 FY27 grew at 13.5%, GSK grew faster than its Rep Market
IPM Q1 FY27 IPM grew at 13.5%, GSK grew faster than its Rep Market IPM sees growth largely on account Within Acute, key therapies like Pain, GSK’s Rep market grew at 10% with both Vx GSK’s performance in metro class and of price. derma grew at 11%; AI grew slower and Gen Med outperforming the market
Slide 5: GSK's key brands remained competitive in the market in Q1 FY27
GSK’s key brands remained competitive in the market in Q1 FY27 GENERAL MEDICINES VACCINES SPECIALTY 1 Gen Meds1 market share improved (+0.6%val MS Established Vaccines continues to lead the Building equity in the 2 4 gain, Val EI 101); key brands delivered competitive overall Vx market with 26.1% Va
Slide 6: Financial Highlights: Q1 FY 26-27 (Standalone)
Financial Highlights : Q1 FY 26-27 (Standalone) Delivering strong growth with continued portfolio transformation Revenue EBITDA PAT ₹924cr ₹293cr ₹253cr Growth +15% Margin: 31.7% (+50 bps) Margin: 27.6% (+200 bps) Growth +17% Growth +24% Revenue growth +15% EBITDA margin +50 bps (YoY) PAT +200 bps (
Slide 7: Consistent competitive performance & profitability improvement with portfolio transformation
Consistent competitive performance & profitability improvement with portfolio transformation 35.9 35.2 Improving profitability 34.4 34.3 Portfolio transformation 31.9 31.7 30.7 31.2 Upcoming Launches 28.3 28 27 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 I
Slide 8: End of Presentation
@ sskcom End of Presentation 55K
GlaxoSmithKline Pharmaceuticals — Q1 FY2026-27 Earnings Presentation on 6ix